There are currently 191 clinical trials in Fort Myers, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Florida Cancer Specialists, Golisano Children's Hospital of Southwest Florida, Lee Memorial Health System and Florida Cancer Specialists South. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
NCT05705401
Recruiting
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Gender:
All
Ages:
40 years and above
Trial Updated:
04/01/2024
Locations: Lee Memorial Health System, Fort Myers, Florida +1 locations
Conditions: HER2-positive Breast Cancer
Register for Updates
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)
NCT05445778
Recruiting
GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/28/2024
Locations: Regional Cancer Center/ Florida Gynecologic Oncology, Fort Myers, Florida
Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Register for Updates
OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)
NCT04757610
Recruiting
A 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.
Gender:
All
Ages:
50 years and above
Trial Updated:
03/26/2024
Locations: ShORe Investigational Site, Fort Myers, Florida
Conditions: Neovascular Age-related Macular Degeneration
Register for Updates
Fenofibrate for Prevention of DR Worsening
NCT04661358
Recruiting
This randomized trial will evaluate the effect of fenofibrate compared with placebo for prevention of diabetic retinopathy (DR) worsening through 6 years of follow-up in eyes with mild to moderately severe non-proliferative DR (NPDR) and no CI-DME at baseline. In addition to evaluating efficacy, this study aims to evaluate the feasibility of a model for ophthalmologists to prescribe or collaborate with a primary care provider such as an internist/endocrinologist to prescribe and monitor the dru... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
03/25/2024
Locations: National Ophthalmic Research Institute, Fort Myers, Florida
Conditions: Diabetic Retinopathy
Register for Updates
Mitral Valve Screening Survey
NCT04736667
Recruiting
This study aims to examine the clinical profile/anatomical characteristics and natural history of patients who subsequently fail screening for transcatheter mitral valve intervention (TMVI).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: HealthPark Medical Center, Fort Myers, Florida
Conditions: Mitral Valve Disease
Register for Updates
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
NCT03242642
Recruiting
Multi-center, global, prospective, non-randomized, interventional, pre-market trial. All subjects enrolled with receive the study device.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: HealthPark Medical Center, Fort Myers, Florida
Conditions: Mitral Valve Regurgitation
Register for Updates
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
NCT05183035
Recruiting
A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin [GO]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse who are unable to receive additional anthracyclines, or in 2nd relapse.
Gender:
All
Ages:
Between 29 days and 21 years
Trial Updated:
03/22/2024
Locations: Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida
Conditions: Acute Myeloid Leukemia
Register for Updates
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
NCT04960709
Recruiting
A global phase 3, multicenter, randomized, trial, to Determine the Efficacy and Safety of Durvalumab in combination with Tremelimumab and Enfortumab Vedotin or Durvalumab in combination with Enfortumab vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or who refuse Cisplantin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer. The goal of the study is to explore the triplet combination of Durvalumab, Tremelimumab and Enfortumab Vedotin in terms of efficacy a... Read More
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
03/21/2024
Locations: Research Site, Fort Myers, Florida
Conditions: Muscle Invasive Bladder Cancer
Register for Updates
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
NCT05500222
Recruiting
This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical Outcome event.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: Covenant Research - Fort Myers, Fort Myers, Florida
Conditions: NASH, Cirrhosis, Liver
Register for Updates
Phase 2b Study of GSK4532990 in Adults With NASH
NCT05583344
Recruiting
The purpose of this study is to measure improvements in liver fibrosis and inflammation with GSK4532990 compared with placebo in participants with NASH and advanced fibrosis on biopsy (F3 or F4). The study duration will be up to 76 weeks including the screening period. The treatment duration will be up to 52 weeks.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/13/2024
Locations: GSK Investigational Site, Fort Myers, Florida
Conditions: Nonalcoholic Fatty Liver Disease
Register for Updates
Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).
NCT05893537
Recruiting
This is a Phase 2, prospective, multicenter, randomized, double-masked, placebo-controlled 104-week study to assess the efficacy, safety, and tolerability of orally delivered CT1812 compared to placebo in participants with GA associated with dry AMD.
Gender:
All
Ages:
50 years and above
Trial Updated:
03/12/2024
Locations: National Ophthalmic Research Institute, Fort Myers, Florida
Conditions: Age-Related Macular Degeneration
Register for Updates
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
NCT05103358
Recruiting
A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes
Gender:
All
Ages:
12 years and above
Trial Updated:
03/12/2024
Locations: Florida Cancer Specialists South Division, Fort Myers, Florida +2 locations
Conditions: Solid Tumor, Tumor, Tumor, Solid, Metastasis, Metastatic Cancer, Cancer, Cancer Metastatic, Tumors, Neoplasms, Neoplasm Metastasis, Advanced Solid Tumor, Advanced Cancer, Malignant Solid Tumor, Malignant Solid Neoplasm, Malignant Neoplasm, Malignant Tumor, TSC, TSC1, TSC2, Metastatic Solid Tumor, Metastatic Neoplasm
Register for Updates